Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Earnings Data
Report Date
Apr 29, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
4.83Last Year’s EPS
4.9Same Quarter Last Year
Moderate Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized broad, multi-product commercial momentum, strong financial performance, substantial R&D investment, and encouraging late-stage pipeline progress (notably Repatha, Meritide, biosimilars, rare disease approvals, and Imdeltra). Key challenges include a significant regulatory action on Tavneos, slower-than-expected event accrual for the olpasiran outcome study, several program deprioritizations, and anticipated near-term sales pressure from biosimilars/generics and seasonal/inventory headwinds. On balance, the positives — sustained growth across multiple franchises, clear 2026 guidance range, and a deep late-stage pipeline — outweigh the notable but addressable setbacks.Company Guidance
Broad Commercial Momentum and Product Breadth
14 products achieved blockbuster status ($1B+), 13 products delivered double-digit sales growth, and 18 products posted record results in 2025, underpinning double-digit revenue and EPS growth for the year.
Strong Full-Year Financial Performance and Guidance
Reported 10% sales growth for 2025, non-GAAP operating margin of 46% for the full year, $8.1B in free cash flow, $6B of debt retired, and 2026 revenue guidance of $37.0B–$38.4B with non-GAAP EPS guidance of $21.60–$23.00.
Repatha — Major Growth Driver
Repatha sales grew 36% year-over-year in 2025 to surpass $3 billion; supported by Vesalius CV Phase III results showing a 25% relative risk reduction for first major CV events and a 36% reduction in heart attack, strengthening positioning in primary and secondary prevention.
Evenity and Bone Franchise Strength
Evenity sales increased 34% in 2025 to $2.1 billion (U.S. +41% driven by volume), holding >60% market share in the bone builder segment and showing a 33% increase in new U.S. patients year-over-year.
Rare Disease and New Approvals
Rare disease portfolio generated more than $5 billion in 2025 and grew ~14% year-over-year (nearly $5.2B); Uplisna/Aplisna (transcript: Uplisna/Eplisna/Vuplisna) received approvals in IgG4-related disease and generalized myasthenia gravis in 2025, with Eplisna sales up 73% to $655M.
Respiratory and Immunology Growth — TestSpire/Taspire/TESSPIRE
TestSpire sales grew ~52% year-over-year to nearly $1.5B for the full year, positioning it as a leading therapy in severe uncontrolled asthma and expanding across respiratory specialties.
Oncology Progress and New Standards of Care
IMDELTRA (Imdeltra) received full FDA approval and became standard of care in second-line small cell lung cancer; Imdeltra generated $627M in full-year sales. BLINCYTO grew 28% to over $1.5B, and the bispecific T-cell engager platform continues to advance through late-stage programs.
Biosimilars Contribution and Momentum
Biosimilars delivered $3.0B in 2025 (37% growth year-over-year) and have contributed more than $13B in cumulative sales since 2018; PAV Blue (biosimilar to EYLEA) reached $700M in 2025.
Increased R&D Investment and Robust Pipeline
Non-GAAP R&D spending rose 22% to a record $7.2B in 2025, with multiple late-stage programs advancing (six global Phase III trials for Meritide, opasiran OCEAN-A outcome study ongoing, positive Phase II data for daxdilimab, and multiple planned pivotal starts).
Capital Return and Investment
Q4 dividend of $2.38 per share (6% increase vs. 2024), $2.2B capex in 2025 with $2.6B expected in 2026 to scale manufacturing and prepare for Meritide, and disciplined balance sheet actions (debt retirement).
AMGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 03, 2026 | $338.59 | $366.20 | +8.15% |
Nov 04, 2025 | $294.60 | $317.59 | +7.81% |
Aug 05, 2025 | $295.56 | $280.38 | -5.14% |
May 01, 2025 | $277.05 | $274.56 | -0.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amgen (AMGN) report earnings?
Amgen (AMGN) is schdueled to report earning on Apr 29, 2026, After Close (Confirmed).
What is Amgen (AMGN) earnings time?
Amgen (AMGN) earnings time is at Apr 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMGN EPS forecast?
AMGN EPS forecast for the fiscal quarter 2026 (Q1) is 4.83.
